ABS553

Anti-phospho KDR/FLK-1/VEGFR2 Antibody (Tyr1059)

from rabbit, purified by affinity chromatography

• Sinónimos: Vascular endothelial growth factor receptor 2, VEGFR-2, Fetal liver kinase 1, FLK-1, Kinase insert domain receptor, KDR, Protein-tyrosine kinase receptor flk-1, CD309
• UNSPSC Code: 12352203
• eCl@ss: 32160702
• NACRES: NA.41

Propiedades

• biological source: rabbit
• Quality Level: 100
• antibody form: affinity isolated antibody
• antibody product type: primary antibodies
• clone: polyclonal
• purified by: affinity chromatography
• species reactivity: human, mouse
• species reactivity (predicted by homology): sheep (based on 100% sequence homology), chicken (based on 100% sequence homology), bovine (based on 100% sequence homology), canine (based on 100% sequence homology), zebrafish (based on 100% sequence homology)
• technique(s): inhibition assay: suitable (peptide); western blot: suitable
• NCBI accession no.: NP_002244
• UniProt accession no.: P35968
• shipped in: wet ice
• target post-translational modification: phosphorylation (pTyr1059)
• Gene Information: human ... KDR(3791)

Descripción

General description

VEGFR2, also known as Fetal liver kinase 1 (FLK-1), Kinase insert domain receptor (KDR), Protein-tyrosine kinase receptor flk-1, or CD309, and encoded by the gene KDR/FLK1/VEGFR2, is a tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. VEGFR2 plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. It also promotes proliferation, survival, migration and differentiation of endothelial cells and influences the reorganization of the actin cytoskeleton. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades including the inositol 1,4,5-trisphosphate pathway and the activation of protein kinase C, and the MAP kinase, AKT and FAK pathways. VEGFR2 is also required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. VEGFR2 isoform 1 is cell membrane bound; isoform 2, 3 are secreted.

Immunogen

Epitope: Cytoplasmic domain

KLH-conjugated linear peptide corresponding to the cytoplasmic domain of human KDR/FLK-1/VEGFR2 phosphorylated at Tyr1059.

Application

Peptide Inhibition Analysis: A 1:500 dilution from a representative lot detected KDR/FLK-1/VEGFR2 in CKR-PAE cell lysates treated with Macrophage Colony Stimulating Factor when antibody was preincubated with or without non-phospho peptide. This antibody did not detect KDR/FLK-1/VEGFR2 in CKR-PAE cell lysates treated with Macrophage Colony Stimulating Factor when antibody was preincubated with corresponding phospho peptide.

Research Category
Signaling

Research Sub Category
Cell Cycle, DNA Replication & Repair

This Anti-phospho KDR/FLK-1/VEGFR2 Antibody (Tyr1059) is validated for use in western blotting & peptide inhibition assay for the detection of phospho KDR/FLK-1/VEGFR2 (Tyr1059).

Quality

Evaluated by Western Blotting in untreated and VEGF treated HUVEC cell lysates.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected KDR/FLK-1/VEGFR2 in VEGF treated HUVEC cell lysate.

Target description

~230 kDa observed

Physical form

Affinity purified

Purified rabbit polyclonal in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Información de seguridad

• Storage Class: 12 - Non Combustible Liquids
• wgk_germany: WGK 1
• flash_point_f: Not applicable
• flash_point_c: Not applicable